SeaStar Medical Q2 net loss $2.0M on $0.3M revenue; NEUTRALIZE-AKI trial 60% enrolled

SeaStar Medical Holding Corp

2025-Q2 EPS reported -$0.58 revenue$631,000

Net loss of $2.0M ($0.18/share) vs $3.2M ($1.03/share) in Q2 2024; revenue from QUELIMMUNE pediatric SCD was $0.3M.
NEUTRALIZE-AKI pivotal trial enrollment reached 125 of 200 patients (60%+); interim DSMB recommendations expected Q3 2025.
Added three new top children's hospital customers; SAVE Surveillance Registry showed 75% 28-day survival in first 20 patients.
Raised total $20.8M through offerings in June ($12.4M), July and August 2025 ($8.4M) to extend cash runway into 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.